Research article
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
-
* Corresponding author: Vincent Vuaroqueaux v.vuaroqueaux@tumorbank.org
1 Stiftung Tumorbank Basel, Lörracherstrasse 50, 4125 Riehen, Switzerland
2 OncoScore AG, Lörracherstrasse 50, 4125 Riehen, Switzerland
3 Swiss Institute for Experimental Cancer Research and Swiss Institute of Bioinformatics, Boveresses 155, Office D208, CH-1006 Epalinges, Switzerland
4 Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
5 Room 2021, Genopode, UNIL Sorge, CH-1015 Lausanne, Switzerland
6 Therapeutics Buck Institute for Age Research 8001 Redwood Blvd., Novato, CA 94945, USA
7 Fachärztin FMH für Pathologie, Chefärztin Pathologie, Brauerstrasse 15,8401 Winterthur, Switzerland
8 Women's Hospital and Breast Cancer Center, Therese-Herzog-Weg 2, 79618 Rheinfelden, Germany
9 Laboratoire d'Oncogénétique/INSERM U735, Centre René Huguenin, 35 rue Dailly, 92210 St-Cloud, France
Breast Cancer Research 2007, 9:R33 doi:10.1186/bcr1681
Published: 29 May 2007Additional files
Additional File 1:
A Word file containing a table presenting the treatment distribution according to the E2F1 status in both data sets.
Format: DOC Size: 34KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional File 2:
A pdf file containing a figure showing Kaplan–Meier analysis (MFS) using E2F1 (30th percentile) performed in data subsets with defined adjuvant treatments: (a) none, (b) hormone, (c) chemotherapy and (d) combined.
Format: PDF Size: 110KB Download file
This file can be viewed with: Adobe Acrobat Reader